and those with PI3K pathway mutations. Interim overall survival (OS) analyses at 31% maturity in patients with ESR1 mutations ...

The event highlighted the significance of biomarkers and treatment strategies for ESR1-positive metastatic breast cancer. Patient awareness varies, with some well-informed and others skeptical of ...

Estrogen functions through binding of two different estrogen receptors (ESRs), ESR1 and ESR2 ... via an effect on the RANK/RANKL/OPG signaling pathway (see following section); Enhancing bone ...

The regulatory filing for the drug did not specify that use should be limited to the ESR1-positive population, so the FDA has approved a narrower label than originally sought when Stemline filed ...

Around 70% of all metastatic breast cancer cases are HR-positive and HER2-negative, and ESR1 mutations are found in up to 40% of these tumours. That suggests there should be plenty of eligible ...

Loss-of-function ESR1 alleles not only predispose an individual ... resorption via upregulation of the RANK/RANKL/OPG signaling pathway. Thus, a strategy that functions to reverse bone resorption ...